IGC News & Events

IGC Pharma announced the beta version of its proprietary Agentic Harmonization Assistant, an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer's and aging-related datasets. "Artificial intelligence is changing how medicines are discovered and developed, but AI models are only as powerful as the data they can learn from," said Ram Mukunda, CEO of IGC Pharma. "Our vision is for AHA to become a trusted infrastructure layer that helps pharmaceutical companies, academic institutions, government agencies, and healthcare data organizations convert fragmented biomedical datasets into interoperable, reusable, and AI-ready discovery assets." In internal testing using an Alzheimer's structured-data workflow involving 100 variables, AHA reduced harmonization time from 28 hours of manual processing to 2.5 hours, including human verification of results - a 90% reduction in workflow time for that representative test case.

IGC Pharma announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The addition of Mount Sinai comes as CALMA advances toward completion, with approximately 80% of targeted participants having completed trial participation.